By early 2025, most 503B outsourcing facilities had stopped tirzepatide production
Injection site reactions are a recognised side effect of tirzepatide, a dual GIP and GLP-1 receptor agonist administered as a weekly subcutaneous injection for type 2 diabetes and weight management
By week 8, many patients have lost 515 pounds total
The findings are intended to inform clinicians, researchers, and policymakers regarding the long-term oncological safety of GLP-1 RAs in patients with T2DM and/or obesity
Constipation hits approximately 24% of Wegovy users and 20-25% of Zepbound users
Pyridoxine supports the synthesis of neurotransmitters (serotonin and dopamine), which help regulate your mood and appetite, enhancing the appetite-suppressing effects of tirzepatide